Form 4: Kyverna Therapeutics Director and 10% Owner Fred E. Cohen Reports Significant Equity Awards

Kyverna Therapeutics, Inc. Director and 10% owner Fred E. Cohen reported the acquisition of 16,634 restricted stock units and 65,351 stock options on May 29, 2025, as part of his compensation.

Summary

• Fred E. Cohen, a Director and 10% owner of Kyverna Therapeutics, Inc. (KYTX), reported new equity awards on May 29, 2025.
• He acquired 16,634 shares of common stock in the form of a restricted stock unit (RSU) award at a price of $0.
• He also acquired 65,351 stock options with an exercise price of $2.63 per share.
• Both the RSU award and the stock options are set to vest in full on the earlier of May 29, 2026, or immediately prior to the Issuer's 2026 annual meeting of stockholders, contingent on his continuous service to the Issuer.
• Following these transactions, Fred E. Cohen directly beneficially owns 16,634 common shares and 65,351 stock options.
• Additionally, he indirectly beneficially owns 4,523,924 common shares through Vida Ventures, LLC, where he is a managing member of the investment advisor, Vida Ventures Advisors, LLC.

Sentiment

Score: 7

Explanation: The filing indicates standard equity compensation for a director and 10% owner, which is generally a positive sign for aligning interests. No negative information or adverse events are present in this disclosure.

Positives

• The issuance of restricted stock units and stock options to a director and 10% owner aligns management incentives with shareholder interests.
• The awards are subject to continuous service, indicating a commitment to retaining key personnel and their ongoing contribution to the company.

Risks

• The vesting of the equity awards is contingent on Fred E. Cohen's continuous service to the Issuer, meaning the awards could be forfeited if his service terminates before the specified vesting dates.

Future Outlook

The vesting schedule for the newly acquired restricted stock units and stock options extends to May 29, 2026, or the 2026 annual meeting, indicating a future commitment period for the reporting person's service to Kyverna Therapeutics, Inc.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common in the biotechnology or pharmaceutical industry for directors and key personnel. Such awards are designed to align the interests of leadership with the long-term performance and growth of the company. While this filing does not provide broader industry trends, it reflects standard corporate governance practices for incentivizing and retaining experienced leadership in the sector.

Comparison to Industry Standards

• The compensation structure involving restricted stock units and stock options with vesting conditions tied to continuous service is a common practice across publicly traded companies, particularly in high-growth sectors like biotechnology.
• While specific comparable companies or projects are not detailed in this filing, such equity awards are standard mechanisms used by companies like Moderna, BioNTech, or Gilead Sciences to incentivize and retain directors and executives, aligning their financial interests with shareholder value creation over time.
• The exercise price of $2.63 for the options would typically be compared to the market price of KYTX stock on the grant date to assess the 'in-the-money' or 'out-of-the-money' status, a standard valuation metric in executive compensation analysis.

Related Party Transactions

• Fred E. Cohen, a director and 10% owner, is a managing member of Vida Ventures Advisors, LLC, which serves as the investment advisor to Vida Ventures, LLC. Vida Ventures, LLC indirectly holds 4,523,924 common shares of Kyverna Therapeutics, Inc.

Stakeholder Impact

• Shareholders: The equity awards granted to a director and 10% owner are intended to align his financial interests with the long-term performance and value creation for shareholders.

Next Steps

• Continued service of Fred E. Cohen to Kyverna Therapeutics, Inc. to fulfill vesting conditions.
• Vesting of restricted stock units and stock options on or before May 29, 2026.
• Potential exercise of stock options by their expiration date of May 29, 2035.

Key Dates

Keywords

Kyverna Therapeutics, KYTX, Fred E. Cohen, Form 4, SEC filing, insider transaction, restricted stock units, stock options, equity awards, director compensation, beneficial ownership